BIOE Seminar: The Transformation of Cystic Fibrosis Therapy

Friday, February 4, 2022
9:00 a.m.-10:00 a.m.
Virtual
Gregg Duncan
gaduncan@umd.edu

Steve Rowe
Department of Medicine
Gregory Fleming James Cystic Fibrosis Research Center
University of Alabama–Birmingham

The Transformation of Cystic Fibrosis Therapy (and opportunities for other diseases of mucus)

This event will be offered in a online format. For those who wish to attend, login details will be sent to current BIOE faculty, affiliates, students, postdocs, and those who have previously asked to subscribe to our seminars listserv. If you do not currently receive our weekly seminars emails but you wish to attend this event, please email Alyssa Tomlinson (awolice@umd.edu).

About the Speaker: 

Steven M. Rowe, MD MSPH is a Professor in the Departments of Medicine (Pulmonary, Allergy, and Critical Care Medicine), Pediatrics (Pediatric Pulmonology), and Cell Developmental and Integrative Biology. He is the Director of the Gregory Fleming Cystic Fibrosis Research Center, which involves over 100 faculty members and has been continuously funded for over 25 years. Dr. Rowe is board certified in Internal Medicine, Pediatrics, Pulmonary Medicine and Critical Care Medicine and serves as a Special Consultant for Translational Science for the Cystic Fibrosis Foundation.

Dr. Rowe is an accomplished academic physician scientist – a pioneer in the field of personalized therapeutics for cystic fibrosis (CF), cutting-edge discovery in airway disease biology, and translational research. He is a respected authority in the design and conduct of clinical trials targeting the basic CF defect and has made key advances in the measurement and interpretation of CF transmembrane conductance regulator (CFTR) function in humans and animals. In a related effort, Dr. Rowe has advanced both the molecular and clinical understanding of suppression of premature termination codons, representing an exciting strategy for treatment of genetic diseases caused by nonsense mutations, which are responsible for approximately 10 percent of all genetic diseases.

Dr. Rowe has recently discovered that COPD patients exhibit acquired CFTR dysfunction through a pathway that causes delayed mucociliary clearance and confers chronic bronchitis. The approach establishes how a single gene in a rare disorder can contribute to the third leading cause of death and has lead to new efforts to evaluate CFTR modulators in patients with chronic bronchitis, potentially leading to a new paradigm for COPD treatment. Dr. Rowe co-invented one-micron resolution optical coherence tomography that captures 3D imaging in real time at the cellular level. The technique is highly sensitive to the epithelial function of airway tissues and can provide simultaneous and non-invasive measurements of the functional microanatomy of the airway surface, significantly advancing our understanding of airway disease pathogenesis.


 

Audience: Public 

remind we with google calendar

 

May 2022

SU MO TU WE TH FR SA
1 2 3 4 5 6 7
8 9 10 11 12 13 14
15 16 17 18 19 20 21
22 23 24 25 26 27 28
29 30 31 1 2 3 4
Submit an Event